Placebo-controlled, Double-blinded Phase III Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer
To compare progression free survival of the standard second line chemotherapy (FOLFIRI,
XELIRI) plus simvastatin in metastatic colorectal cancer patients. This trial is a
placebo-controlled study.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Progression free survival
12 months
No
Won Ki Kang, MD
Principal Investigator
Samsung Medical Center
Korea: Food and Drug Administration
2009-11-017
NCT01238094
April 2010
May 2014
Name | Location |
---|